Giuseppe
Emeritus
HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals (Trono et al. 329 (5988): 174, Science, abstract, edited)
[Source: Science, <cite cite="http://www.sciencemag.org/cgi/content/abstract/329/5988/174">HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals -- Trono et al. 329 (5988): 174 -- Science</cite>. Abstract, edited.]
Science 9 July 2010: Vol. 329. no. 5988, pp. 174 - 180
DOI: 10.1126/science.1191047
Review
HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals
Didier Trono,1,* Carine Van Lint,2 Christine Rouzioux,3 Eric Verdin,4 Fran?oise Barr?-Sinoussi,5 Tae-Wook Chun,6, Nicolas Chomont7,
HIV infection can persist in spite of efficacious antiretroviral therapies. Although incomplete inhibition of viral replication may contribute to this phenomenon, this is largely due to the early establishment of a stable reservoir of latently infected cells. Thus, life-long antiviral therapy may be needed to control HIV. Such therapy is prone to drug resistance and cumulative side effects and is an unbearable financial burden for regions of the world hit hardest by the epidemic. This review discusses our current understanding of HIV persistence and the limitations of potential approaches to eradicate the virus and accordingly pleads for a joint multidisciplinary effort toward two highly related goals: the development of an HIV prophylactic vaccine and the achievement of long-term drug-free remissions in HIV-infected individuals.
1 School of Life Sciences and Frontiers-in-Genetics Program, ?cole Polytechnique F?d?rale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
2 Institut de Biologie et de M?decine Mol?culaires (IBMM), Universit? Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.
3 CHU Necker, Universit? Paris Descartes, 75743 Paris, France.
4 Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA.
5 Department of Virology, Unit of Regulation of Retroviral Infections, Institut Pasteur, 75015 Paris, France.
6 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
7 Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL 34987, USA.
These authors contributed equally to this work.
*To whom correspondence should be addressed. E-mail: Didier.trono@epfl.ch
-
-----
[Source: Science, <cite cite="http://www.sciencemag.org/cgi/content/abstract/329/5988/174">HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals -- Trono et al. 329 (5988): 174 -- Science</cite>. Abstract, edited.]
Science 9 July 2010: Vol. 329. no. 5988, pp. 174 - 180
DOI: 10.1126/science.1191047
Review
HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals
Didier Trono,1,* Carine Van Lint,2 Christine Rouzioux,3 Eric Verdin,4 Fran?oise Barr?-Sinoussi,5 Tae-Wook Chun,6, Nicolas Chomont7,
HIV infection can persist in spite of efficacious antiretroviral therapies. Although incomplete inhibition of viral replication may contribute to this phenomenon, this is largely due to the early establishment of a stable reservoir of latently infected cells. Thus, life-long antiviral therapy may be needed to control HIV. Such therapy is prone to drug resistance and cumulative side effects and is an unbearable financial burden for regions of the world hit hardest by the epidemic. This review discusses our current understanding of HIV persistence and the limitations of potential approaches to eradicate the virus and accordingly pleads for a joint multidisciplinary effort toward two highly related goals: the development of an HIV prophylactic vaccine and the achievement of long-term drug-free remissions in HIV-infected individuals.
1 School of Life Sciences and Frontiers-in-Genetics Program, ?cole Polytechnique F?d?rale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
2 Institut de Biologie et de M?decine Mol?culaires (IBMM), Universit? Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.
3 CHU Necker, Universit? Paris Descartes, 75743 Paris, France.
4 Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA.
5 Department of Virology, Unit of Regulation of Retroviral Infections, Institut Pasteur, 75015 Paris, France.
6 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
7 Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL 34987, USA.
These authors contributed equally to this work.
*To whom correspondence should be addressed. E-mail: Didier.trono@epfl.ch
-
-----